|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C12N 9/18 | |
| A61K 38/46 | |||
| A61K 31/135 | |||
| A61K 31/366 | |||
| A61K 31/397 | |||
| A61K 31/465 | |||
| A61P 3/06 |
| (11) | Number of the document | 2977057 |
| (13) | Kind of document | T |
| (96) | European patent application number | 14200334.2 |
| Date of filing the European patent application | 2011-09-09 | |
| (97) | Date of publication of the European application | 2016-01-27 |
| (45) | Date of publication and mention of the grant of the patent | 2019-11-06 |
| (46) | Date of publication of the claims translation |
| (30) | Number | Date | Country code |
| 403011 P | 2010-09-09 | US | |
| 456014 P | 2010-10-29 | US | |
| 201161432372 P | 2011-01-13 | US | |
| PCT/US2011/0336 | 2011-04-23 | WO |
| (72) |
Quinn, Anthony, US
|
| (73) |
Alexion Pharmaceuticals, Inc.,
121 Seaport Boulevard, Boston, MA 02210,
US
|
| (54) | ISOLATED RECOMBINANT HUMAN N-GLYCOSYLATED LYSOSOMAL ACID LIPASE |
| ISOLATED RECOMBINANT HUMAN N-GLYCOSYLATED LYSOSOMAL ACID LIPASE |